Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, recently announced the approval of a Chinese patent for their HT-KIT technology, aimed at inducing apoptosis in cancer cells. This move expands their protection in the global oncology market, one of the largest in the world. The news was made public on January 21, 2026, as the company secures its intellectual property rights for this innovative technology. Hoth Therapeutics continues to make strides in the field of oncology with this significant development.